The Tofacitinib and NAC treatment groups received daily subcutaneous administration of their respective drugs using the microneedle system from day 8 to day 28 post-induction thereby enabling comparative assessment of the effects of JAK-STAT pathway inhibition and antioxidant therapy on RA pathophysiology. This evidence concerns the gene SOAT1 and rheumatoid arthritis.